Name | Number of supported studies | Average coverage | |
---|---|---|---|
goblet cell | 9 studies | 33% ± 10% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 33% ± 8% | |
mucus secreting cell | 3 studies | 63% ± 13% | |
luminal cell of prostate epithelium | 3 studies | 31% ± 2% |
Insufficient scRNA-seq data for expression of TFF1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 91% | 34936.39 | 328 / 359 | 64% | 1404.36 | 184 / 286 |
intestine | 46% | 352.10 | 443 / 966 | 71% | 1251.22 | 372 / 527 |
prostate | 85% | 375.38 | 208 / 245 | 14% | 42.27 | 71 / 502 |
thymus | 94% | 203.67 | 612 / 653 | 0% | 0 | 0 / 605 |
pancreas | 23% | 104.21 | 74 / 328 | 70% | 2657.78 | 125 / 178 |
breast | 24% | 78.50 | 108 / 459 | 58% | 1523.09 | 650 / 1118 |
esophagus | 9% | 42.55 | 137 / 1445 | 33% | 683.00 | 60 / 183 |
bladder | 14% | 26.10 | 3 / 21 | 26% | 334.01 | 130 / 504 |
lung | 2% | 21.96 | 11 / 578 | 16% | 448.99 | 182 / 1155 |
liver | 6% | 3.20 | 14 / 226 | 4% | 48.21 | 16 / 406 |
uterus | 2% | 1.14 | 4 / 170 | 5% | 55.44 | 24 / 459 |
adrenal gland | 3% | 1.65 | 9 / 258 | 0% | 0.89 | 1 / 230 |
ovary | 2% | 0.87 | 4 / 180 | 0% | 1.92 | 2 / 430 |
adipose | 2% | 26.65 | 27 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 2% | 1.64 | 21 / 1335 | 0% | 0 | 0 / 0 |
skin | 1% | 1.39 | 25 / 1809 | 0% | 0 | 0 / 472 |
spleen | 1% | 0.55 | 3 / 241 | 0% | 0 | 0 / 0 |
heart | 1% | 3.78 | 6 / 861 | 0% | 0 | 0 / 0 |
muscle | 1% | 1.56 | 5 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 0.45 | 5 / 929 | 0% | 0 | 0 / 0 |
brain | 0% | 0.23 | 12 / 2642 | 0% | 0 | 0 / 705 |
kidney | 0% | 0 | 0 / 89 | 0% | 1.86 | 2 / 901 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0005975 | Biological process | carbohydrate metabolic process |
GO_0035902 | Biological process | response to immobilization stress |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0010039 | Biological process | response to iron ion |
GO_0008283 | Biological process | cell population proliferation |
GO_0030277 | Biological process | maintenance of gastrointestinal epithelium |
GO_0030154 | Biological process | cell differentiation |
GO_0043434 | Biological process | response to peptide hormone |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005515 | Molecular function | protein binding |
GO_0008083 | Molecular function | growth factor activity |
Gene name | TFF1 |
Protein name | Trefoil factor 1 (Breast cancer estrogen-inducible protein) (PNR-2) (Polypeptide P1.A) (hP1.A) (Protein pS2) |
Synonyms | BCEI PS2 |
Description | FUNCTION: Stabilizer of the mucous gel overlying the gastrointestinal mucosa that provides a physical barrier against various noxious agents. May inhibit the growth of calcium oxalate crystals in urine. . |
Accessions | P04155 ENST00000291527.3 |